Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b/3 study of Lunsekimig in eosinophilic uncontrolled COPD
MOH_2025-10-28_015417Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Oct 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of lunsekimig, sponsored by Sanofi. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
lunsekimig
Beyond the preview
Go deeper on MOH_2025-10-28_015417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-10-28_015417.